| Anthony Kokoszka Ii, MS, OTR/L | |
|
17436 Slipper Shell Way Unit 19, Lewes, DE 19958-6319 | |
| (302) 354-1216 | |
| Not Available |
| Full Name | Anthony Kokoszka Ii |
|---|---|
| Gender | Male |
| Speciality | Occupational Therapist |
| Location | 17436 Slipper Shell Way Unit 19, Lewes, Delaware |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588166862 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | U1-0001816 (Delaware) | Primary |
| Provider Name | Fox Rehabilitation Services Inc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1326092503 PECOS PAC ID: 0143133009 Enrollment ID: O20040407000721 |
News Archive
Researchers from the Netherlands have shown that physical activity in patients with chronic obstructive pulmonary disease is influenced by both physical and psychosocial factors.
Following an earlier study that validated the loss of smell and taste as indicators of SARS-CoV-2 infection, researchers at UC San Diego Health report in newly published findings that olfactory impairment suggests the resulting COVID-19 disease is more likely to be mild to moderate, a potential early indicator that could help health care providers determine which patients may require hospitalization.
New research reports that women with systemic lupus erythematosus (SLE) have a two-fold increase in risk of preeclampsia—a dangerous condition in which pregnant women develop high blood pressure (hypertension) and protein in their urine (proteinuria) after 20 weeks of gestation
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results and operational highlights for the quarter ended September 30, 2010.
Merck, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS (boceprevir) for the treatment of chronic hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anthony Kokoszka Ii, MS, OTR/L 17436 Slipper Shell Way Unit 19, Lewes, DE 19958-6319 Ph: () - | Anthony Kokoszka Ii, MS, OTR/L 17436 Slipper Shell Way Unit 19, Lewes, DE 19958-6319 Ph: (302) 354-1216 |
News Archive
Researchers from the Netherlands have shown that physical activity in patients with chronic obstructive pulmonary disease is influenced by both physical and psychosocial factors.
Following an earlier study that validated the loss of smell and taste as indicators of SARS-CoV-2 infection, researchers at UC San Diego Health report in newly published findings that olfactory impairment suggests the resulting COVID-19 disease is more likely to be mild to moderate, a potential early indicator that could help health care providers determine which patients may require hospitalization.
New research reports that women with systemic lupus erythematosus (SLE) have a two-fold increase in risk of preeclampsia—a dangerous condition in which pregnant women develop high blood pressure (hypertension) and protein in their urine (proteinuria) after 20 weeks of gestation
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results and operational highlights for the quarter ended September 30, 2010.
Merck, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS (boceprevir) for the treatment of chronic hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.
› Verified 7 days ago
Callie Mcdowell, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 17344 Sweetbriar Rd, Lewes, DE 19958 Phone: 302-645-7210 | |
Candace Shetzler, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1002 Kings Hwy, Lewes, DE 19958 Phone: 302-645-2153 | |
Shannon Deck, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 301 Ocean View Blvd, Lewes, DE 19958 Phone: 302-645-4664 | |
Kassandra Soldevilla, OTR Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 701 Savannah Rd, Lewes, DE 19958 Phone: 302-644-2530 | |
Taylor Swain, OT Occupational Therapist Medicare: Medicare Enrolled Practice Location: 20268 Plantations Rd Ste B, Lewes, DE 19958 Phone: 302-727-0075 Fax: 302-449-2047 | |
Dynamic Therapy Services Llc Occupational Therapist Medicare: Medicare Enrolled Practice Location: 701 Savannah Rd Ste A, Lewes, DE 19958 Phone: 302-644-2530 | |
Camilla Harrod, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1270 Kings Hwy, Lewes, DE 19958 Phone: 302-645-6686 |